Latest news

• Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

  drugs. New therapies like Novartis’ heart failure therapy Entresto (sacubitril/valsartan) and cholesterol-lowering PCSK9 inhibitors from Amgen and Sanofi/Regeneron have re-injected growth into the market, although they have

• TMC preps filings for inclisiran after final phase 3 trials hit the mark

  If approved, inclisiran will compete most closely with two antibody-based PCSK9 inhibitors – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – but will offer efficacy that is at least ... Alnylam-partnered inclisiran is

• TMC rockets on data for twice-yearly cholesterol drug inclisiran

  The small, interfering RNA (siRNA) drug – which works by blocking the synthesis of PCSK9 in the liver – was being tested in patients with atherosclerotic cardiovascular disease (ASCVD) who were unable to ... That is a much less frequent dosing

• Regeneron scores positive data in phase 3 cholesterol trial

  Despite patients already taking lipid-lowering treatments, such as statins and PCSK9 inhibitors, their levels of cholesterol remained dangerously high prior to enrolment in the study. ... Regeneron and partner Sanofi have another approved

• England opens new NHS ‘front door’ to health innovators

  Most significantly for pharma, only two of these areas related to medicines: the PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia, Amgen’s Repatha and Sanofi’s Praluent, as